Akums introduces Amlodipine, Telmisartan & Metoprolol (ER) film coated tablets for hypertension management

New Delhi: Hypertension, a pervasive health challenge associated with significant mortality and long-term morbidity, remains a formidable obstacle in healthcare worldwide. As a major risk factor for vascular diseases such as cerebrovascular disease, ischemic heart disease, cardiac failure, and renal failure, hypertension's impact on global health cannot be overstated. The projected increase in cardiovascular-related mortality underscores the urgent need for effective treatment strategies, particularly in developing countries where the burden is most acute.

Recognising the pressing need for solutions, Akums Drugs and Pharmaceuticals introduced Amlodipine, Telmisartan & Metoprolol (ER) film coated tablets, a fixed-dose combination (FDC) medication for the management of uncontrolled essential hypertension with stable coronary artery disease. This FDC integrates the therapeutic benefits of three well-established medications into a single, convenient tablet, offering a comprehensive approach to blood pressure control.

With the approval from the Drugs Controller General of India (DCGI), Amlodipine, Telmisartan & Metoprolol (ER) Film Coated Tablets represent an advancement in cardiovascular care.

By combining the therapeutic benefits of calcium channel blockers, angiotensin II receptor antagonists, and beta-adrenergic blockers, this FDC offers a comprehensive approach to blood pressure control.

The individual mechanism of action of each component contributes to the FDC's efficacy in hypertension management. Amlodipine, by blocking voltage-dependent L-type calcium channels, induces vasodilation and decreases vascular smooth muscle contractility, thereby lowering blood pressure. Telmisartan selectively inhibits the angiotensin II AT1 receptor subtype, promoting blood vessel relaxation. Metoprolol (ER), a cardio-selective beta-1-adrenergic receptor inhibitor, reduces cardiac output through negative inotropic and chronotropic effects.

Single-pill triple combinations of different classes of drugs with complementary mechanisms of action help to treat patients to a goal with improved efficacy and better adherence to treatment. Thus, this fixed-dose of triple medications used as a single pill will improve patient’s dose compliance leading to better long-term BP control.

Having received approval from the Drugs Controller General of India (DCGI), Amlodipine, Telmisartan & Metoprolol (ER) film coated tablets are set to make an impact in the cardiovascular segment. This represents an additional therapeutic approach to manage hypertension, offering a convenient approach that addresses multiple aspects of blood pressure regulation. Its introduction marks a step forward in the ongoing effort to combat hypertension and its associated complications, ultimately improving the quality of life for patients.